% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Svaina:1005757,
      author       = {Svačina, Martin K. R. and Sprenger-Svačina, Alina and
                      Tsakmaklis, Anastasia and Rüb, Alina M. and Klein, Ines and
                      Wüstenberg, Hauke and Fink, Gereon R. and Lehmann, Helmar
                      C. and Vehreschild, Maria J. G. T. and Farowski, Fedja},
      title        = {{T}he gut microbiome in intravenous
                      immunoglobulin‐treated chronic inflammatory demyelinating
                      polyneuropathy},
      journal      = {European journal of neurology},
      volume       = {30},
      number       = {11},
      issn         = {1351-5101},
      address      = {Oxford [u.a.]},
      publisher    = {Wiley-Blackwell},
      reportid     = {FZJ-2023-01611},
      pages        = {3551-3556},
      year         = {2023},
      abstract     = {AbstractBackground and purpose: The gut microbiome is
                      involved in autoimmunity. Data on its composition in chronic
                      inflammatory demyelinating polyneuropathy (CIDP), the most
                      common chronic autoimmune disorder of peripheral nerves, are
                      currently lacking.Methods: In this monocentric exploratory
                      pilot study, stool samples were prospectively collected from
                      16 CIDP patients (mean age 58 ± 10 years, $25\%$ female)
                      before and 1 week after administration of intravenous
                      immunoglobulin (IVIg). Gut microbiota were analyzed via
                      bacterial 16S rRNA gene sequencing and compared to 15
                      age-matched healthy subjects (mean age 59 ± 15 years,
                      $66\%$ female).Results: The gut microbiota of CIDP patients
                      showed an increased alpha-diversity (p = 0.005) and
                      enrichment of Firmicutes, such as Blautia (p = 0.0004),
                      Eubacterium hallii (p = 0.0004), or Ruminococcus torques (p
                      = 0.03), and of Actinobacteriota (p = 0.03) compared to
                      healthy subjects. IVIg administration did not alter the gut
                      microbiome composition in CIDP in this short-term
                      observation (p = 0.95).Conclusions: The gut microbiome in
                      IVIg-treated CIDP shows distinct features, with increased
                      bacterial diversity and enrichment of short-chain fatty acid
                      producing Firmicutes. IVIg had no short-term impact on the
                      gut microbiome in CIDP patients. As the main limitation of
                      this exploratory pilot study was small cohort size, future
                      studies also including therapy-naïve patients are warranted
                      to verify our findings and to explore the impact of
                      long-term IVIg treatment on the gut microbiome in
                      CIDP.Keywords: autoimmunity; firmicutes; immune
                      neuropathies; intestinal barrier; short-chain fatty acids
                      (SCFA).},
      cin          = {INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406},
      pnm          = {5251 - Multilevel Brain Organization and Variability
                      (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5251},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {36651357},
      UT           = {WOS:000925036100001},
      doi          = {10.1111/ene.15679},
      url          = {https://juser.fz-juelich.de/record/1005757},
}